logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Metastatic Human Epidermal Growth Factor 2 Positive Carcinoma Of Breast

    FiltersReset Filters
    6 results

    • enhertu

      (fam-trastuzumab deruxtecan-nxki)
      Daiichi Sankyo Inc.
      Usage: ENHERTU is indicated for treating adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low or HER2-ultralow breast cancer, HER2-mutant non-small cell lung cancer, advanced HER2-positive gastric cancer, and unresectable HER2-positive solid tumors, all following prior systemic therapies.

    • kadcyla

      (ADO-TRASTUZUMAB EMTANSINE)
      Genentech, Inc.
      Usage: KADCYLA is indicated for treating HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, or for early breast cancer in those with residual disease after neoadjuvant therapy. Patient selection should use an FDA-approved companion diagnostic.

    • margenza

      (margetuximab-cmkb)
      MacroGenics, Inc
      Usage: MARGENZA is indicated for treating adult patients with metastatic HER2-positive breast cancer, in combination with chemotherapy, who have previously received two or more anti-HER2 regimens, including one for metastatic disease.

    • perjeta

      (Pertuzumab)
      Genentech, Inc.
      Usage: PERJETA is indicated for treating adults with HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel, as well as for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy.

    • phesgo

      (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
      Genentech, Inc.
      Usage: PHESGO is indicated for combination with chemotherapy in adults with HER2-positive early breast cancer for neoadjuvant and adjuvant treatment, and for those with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy. Patient selection is based on an FDA-approved diagnostic test.

    • tukysa

      (tucatinib)
      SEAGEN INC.
      Usage: TUKYSA is indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, and for those with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed after standard chemotherapy. It requires prior anti-HER2 therapy for approval.